News
Investor's Business Daily on MSN21m
Kenvue Surges After Tylenol-Maker Announces Sweeping ChangesKenvue stock surged Monday after the company — known for brands like Tylenol — announced sweeping changes, including naming a ...
Investor's Business Daily on MSN33m
Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A RejectionUltragenyx Pharmaceuticals took another hit when the FDA rejected its gene therapy for patients with a rare, genetic disorder.
Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback